Stay updated on Upadacitinib vs Placebo in RA Clinical Trial
Sign up to get notified when there's something new on the Upadacitinib vs Placebo in RA Clinical Trial page.

Latest updates to the Upadacitinib vs Placebo in RA Clinical Trial page
- Check5 days agoChange DetectedAdded a site-wide government funding notice and updated the site revision to v3.4.1, and removed related topics (Rheumatoid arthritis) and the older revision tag (v3.4.0); to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check12 days agoChange DetectedUI updates include showing the glossary, updating the QC update label to 'Last Update Submitted that Met QC Criteria', and revising No FEAR Act text with a version bump from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page revision label changed from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check41 days agoChange DetectedAdded a 'Rheumatoid arthritis' tag and a Related topics section linking to MedlinePlus Genetics to aid navigation.SummaryDifference0.1%

- Check48 days agoChange DetectedLocations section reorganized into a single 'Locations' list (Aichi-ken, Fukuoka, Gunma, Hokkaido, Hyōgo, Kanagawa, Kawachinagano-shi, Kumamoto, Miyagi, Miyazaki, Niigata, Saitama, Tochigi, Tokyo, Yamaguchi) and includes a 'Revision: v3.3.3' tag. The previous 'X Locations' subsections were removed.SummaryDifference1%

- Check55 days agoChange DetectedThe Rheumatoid arthritis topic and the related MedlinePlus Genetics section have been removed from the page. This reduces visible disease-context on the study details page and may affect how users access disease-specific information.SummaryDifference0.1%

Stay in the know with updates to Upadacitinib vs Placebo in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upadacitinib vs Placebo in RA Clinical Trial page.